Positive News SentimentPositive NewsNASDAQ:TCRT Alaunos Therapeutics (TCRT) Stock Price, News & Analysis $2.12 +0.05 (+2.61%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Alaunos Therapeutics Stock (NASDAQ:TCRT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alaunos Therapeutics alerts:Sign Up Key Stats Today's Range$2.06▼$2.2350-Day Range$1.97▼$3.0652-Week Range$1.67▼$6.20Volume12,177 shsAverage Volume17,798 shsMarket Capitalization$51.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. Read More Alaunos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreTCRT MarketRank™: Alaunos Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 767th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAlaunos Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAlaunos Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Alaunos Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Alaunos Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alaunos Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlaunos Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Alaunos Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Alaunos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlaunos Therapeutics has a short interest ratio ("days to cover") of 0.53, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alaunos Therapeutics has recently decreased by 16.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlaunos Therapeutics does not currently pay a dividend.Dividend GrowthAlaunos Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentAlaunos Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Alaunos Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Alaunos Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.14% of the stock of Alaunos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.72% of the stock of Alaunos Therapeutics is held by institutions.Read more about Alaunos Therapeutics' insider trading history. Receive TCRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCRT Stock News HeadlinesAlaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | finanznachrichten.deAlaunos reports positive preclinical obesity drug results across weight, liver, insulin markersMay 26, 2026 | msn.comMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year with a 279% return on cash while the S&P returned 15%. Now Benedict says the SpaceX IPO has triggered the 'Final Phase of Elon's Master Plan,' with billions potentially flowing into a single ticker. He's revealing the name and ticker today, free of charge.June 26 at 1:00 AM | Brownstone Research (Ad)Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | globenewswire.comAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity ModelsMay 18, 2026 | globenewswire.comWeight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares DropMarch 2, 2026 | benzinga.comAlaunos Reports Positive Preclinical Data for Obesity CandidateMarch 2, 2026 | tipranks.comAlaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersMarch 2, 2026 | globenewswire.comSee More Headlines TCRT Stock Analysis - Frequently Asked Questions How have TCRT shares performed this year? Alaunos Therapeutics' stock was trading at $3.23 at the beginning of the year. Since then, TCRT shares have decreased by 34.4% and is now trading at $2.12. How were Alaunos Therapeutics' earnings last quarter? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) issued its earnings results on Friday, May, 15th. The company reported ($0.59) earnings per share for the quarter. When did Alaunos Therapeutics' stock split? Shares of Alaunos Therapeutics reverse split on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Alaunos Therapeutics? Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alaunos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alaunos Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/15/2026Today6/26/2026Next Earnings (Estimated)8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 10 days, TCRT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCRT CIK1107421 Webwww.alaunos.com Phone(346) 355-4099Fax617-241-2855Employees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.18 million Net MarginsN/A Pretax Margin-136,966.67% Return on Equity-165.94% Return on Assets-123.50% Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book2.28Miscellaneous Outstanding Shares24,420,000Free Float20,480,000Market Cap$51.87 million OptionableNo Data Beta-1.07 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:TCRT) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker includedTired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
